Key points are not available for this paper at this time.
This interim report presents the 12-week results of a post-marketing surveillance evaluating the safety of desmopressin orally disintegrating tablets 25 and 50 μg in Japanese men with nocturia due to nocturnal polyuria.
Ogawa et al. (Mon,) studied this question.